322 related articles for article (PubMed ID: 32213059)
1. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
[TBL] [Abstract][Full Text] [Related]
2. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
Govani SM; Higgins PD
J Crohns Colitis; 2010 Oct; 4(4):444-9. PubMed ID: 21122542
[TBL] [Abstract][Full Text] [Related]
3. Thiopurines with low-dose allopurinol (ThiLDA)-a prospective clinical one-way crossover trial.
Chavoushi SF; Jharap B; Friedrich P; Smid K; Peters GJ; Malingré M
Eur J Clin Pharmacol; 2019 Dec; 75(12):1669-1674. PubMed ID: 31587102
[TBL] [Abstract][Full Text] [Related]
4. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
Jagt JZ; Pothof CD; Buiter HJC; van Limbergen JE; van Wijk MP; Benninga MA; de Boer NKH; de Meij TGJ
Dig Dis Sci; 2022 Jan; 67(1):241-251. PubMed ID: 33532972
[TBL] [Abstract][Full Text] [Related]
6. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
9. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
10. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
11. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
[TBL] [Abstract][Full Text] [Related]
12. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
Kiszka-Kanowitz M; Theede K; Mertz-Nielsen A
Scand J Gastroenterol; 2016 Dec; 51(12):1470-1475. PubMed ID: 27686002
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
[TBL] [Abstract][Full Text] [Related]
16. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
[TBL] [Abstract][Full Text] [Related]
17. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
18. Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study.
Pavlidis P; Stamoulos P; Abdulrehman A; Kerr P; Bull C; Duley J; Ansari A
Inflamm Bowel Dis; 2016 Jul; 22(7):1639-46. PubMed ID: 27271488
[TBL] [Abstract][Full Text] [Related]
19. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.
Rahhal RM; Bishop WP
Inflamm Bowel Dis; 2008 Dec; 14(12):1678-82. PubMed ID: 18521913
[TBL] [Abstract][Full Text] [Related]
20. 6-Mercaptopurine for Azathioprine Intolerant Inflammatory Bowel Disease: Literature Search and Reappraisal of Own Data.
Actis GC; Pellicano R; Rosina F
Inflamm Allergy Drug Targets; 2015; 14(2):133-7. PubMed ID: 26728773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
